View Older Stories View More Recent Stories
-
Notable Analyst Rating Changes 9/9: (GS) (CIEN) (WBA) Upgraded; (MNKD) (GOL) (MOBL) Downgraded
-
Roth Capital Downgrades Quiksilver (ZQK) to Sell
-
Roth Capital reiterated remains Bullish on Roth Capital Sequential Brands (SQBG) Following signed Licensing Agreement
-
Roth Capital Downgrades Yingli Green Energy (YGE) to Sell
-
Sphere 3D to Participate at ROTH Datacenter Technology Corporate Access Day in San Francisco on September 9, 2015
-
Roth Capital Remains Bullish on Plantronics (PLT) Following Investor Day
-
Roth Capital Sees Attractive Risk/Reward for uniQure (QURE) Into Sanfilippo Abstract
-
InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire InSite for $0.35 per Share in Cash Constitutes a “Company Superior Proposal”
-
InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share From a Global Pharmaceutical Company
-
BIO Announces Presenting Companies for 14th Annual BIO Investor Forum
-
Roth Capital Affirms Sarepta (SRPT) at 'Buy'; Shapeshifting Bears Back to Where It Started
-
Roth Capital Reiterates Buy on Performance Sports Group (PSG) Following Analyst and Investor Event
-
Roth Capital Raises Price Target on Lannett (LCI) Following Acquisition of Kremers Urban Pharmaceuticals
-
Lannett To Acquire Kremers Urban Pharmaceuticals For $1.23 Billion
-
ROTH Capital Partners to Host Solar Symposium at Solar Power International (SPI 15)
-
Roth Capital Reiterates Buy on Ligand Pharma (LGND) Following E.U. Approval of Promacta
-
Ligand Pharma (LGND) Reaffirmed at 'Buy' by Roth Following European Promacta Approval, Evomela Update
-
Roth Capital Cuts Price Target on Crossroads Systems (CRDS) Ahead of 3Q Results
-
InterCloud Systems to Present at the 4th Annual Liolios Gateway Conference on September 9, 2015
-
Roth Capital Reiterates Buy on Trevena (TRVN) Following TRV130’s Phase 2b Results
-
Roth Capital Positive on SolarEdge (SEDG) Following Recent Investor Meetings
-
Roth Updates Ests on Adept Technology (ADEP) Following Q4 Results, Outlook; Maintains 'Buy' Rating
-
Streetinsider.com's Hot Lunchtime Reads 8/28: (GME) (GB) (FXI) (ADP)
-
Roth Capital Trims Ests on Sky Solar (SKYS) Following Q2 Results; Sees Close to Securing Capital
-
4th Annual Liolios Gateway Conference to Showcase More Than 90 Growth Companies in San Francisco on September 9-10
-
Roth Capital Re-Starts RMG Networks Holding (RMGN) at Buy
-
Roth Capital Starts Cerulean Pharma (CERU) at Buy, $9 PT
-
Applied Genetic Tech (AGTC) Triggers Enrollment Milestone in XLRS Phase I/II; Roth Affirms at 'Buy'
-
Roth Capital Cuts Price target on Tilly's, Inc. (TLYS) to $12 Following EPS Beat
-
GigOptix, Inc. Closes Public Offering of Common Stock to Support Enhanced Strategic Growth Through Acquisitions
-
Verastem (VSTM) Sell-Off 'Ignores Main Value Driver', Roth Capital Says
-
Roth Capital Remains Bullish on SolarCity (SCTY) Following Investor Meetings
-
SolarCity (SCTY) Remains 'Top Pick' at Roth Following Investor Meetings
-
MoSys to Participate at the ROTH Capital Datacenter Technology Corporate Access Day on September 9
-
Roth Capital Sees Opportunity of Year-End Approval for Sarepta's (SRPT) Eteplirsen; PT Lifted to $50
-
Roth Capital Highlights Biotech Picks 'for the Turn' and Over the Long Haul (PTN) (LGND) (TGTX) (CLDX)
-
ROTH Capital Partners to Host DataCenter Technology Corporate Access Day in San Francisco, Calif. on September 9, 2015
-
Roth Capital Starts Quantum Corp. (QTM) at Buy
-
Streetinsider.com's Hot Lunchtime Reads 8/24: (AAPL) (LGND) (MON) (FCAU)
-
Roth Capital Affirms Ligand Pharma (LGND) at 'Buy' Following Expanded Promacta Indication
-
Roth Capital Positive on Peregrine Pharma (PPHM) Amid New Immunotherapy Collaboration (AZN)
-
Roth Capital Cuts Price Target on Synergy Resources (SYRG) to Reflect New Oil Price Forecast.
-
Notable Analyst Rating Changes 8/21: (SYMC) (CMPR) (CSIQ) Upgraded; (CPA) (LUX) (SSI) Downgraded
-
Roth Capital Positive on BioBlast Pharma (ORPN) Following Q2 Report; H215 Should be Busy with Phase 3 Initiations
-
Roth Capital Starts Hanwha Q CELLS (HQCL) at Buy
-
GigOptix (GIG) Prices 9.22M Common Stock Offering at $1.70/Share
-
GigOptix, Inc. Announces Pricing of Public Offering of Common Stock to Support Enhanced Strategic Growth Through Acquisitions
-
GigOptix (GIG) Announces Common Stock Offering
-
GigOptix, Inc. Announces Proposed Public Offering of Common Stock to Support Enhanced Strategic Growth Through Acquisitions
-
Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q2 Results; BL-8040 Continues to be Main Driver

